Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers

S H L Thomas, M J O'Doherty, A Graham, C J Page, P Blower, D M Geddes, T O Nunan

Abstract

Background Preliminary evidence suggests that regular inhalation of nebulised amiloride reduces sputum viscoelasticity, increases the clearance of sputum by mucociliary mechanisms and by coughing and reduces the rate of deterioration in lung function in patients with cystic fibrosis. These effects depend on adequate delivery of amiloride to the airways. This study was performed to quantify and compare pulmonary deposition of amiloride produced by two different nebuliser systems.

Methods The pulmonary deposition of nebulised amiloride (1 mg in 3 ml saline) was measured in eight patients with cystic fibrosis when given via a jet (System 22 with CR 60 compressor) and an ultrasonic (Fisoneb) nebuliser. Human serum albumin labelled with technetium-99m was used as an indirect marker for amiloride and its deposition in the lung was detected with a gamma camera.

Results Amiloride inhalation caused no side effects or changes in spirometric indices. The mean (SD) total pulmonary amiloride deposition was 57 (24) μg with the System 22 and 103 (53) μg with the Fisoneb nebuliser. Pulmonary deposition was completed more rapidly with the Fisoneb (4-5 minutes) than with the System 22 nebuliser (7-8 minutes) and the Fisoneb was preferred by the patients.

Conclusions Both nebulisers appeared to deliver adequate amounts of amiloride to the lungs, but treatment with the Fisoneb nebuliser was quicker, more efficient, and more acceptable to the patients. Of the two nebulisers assessed, the Fisoneb would be preferred for clinical trials.

Cystic fibrosis is associated with increased sodium absorption, reduced chloride conductance, and an increased potential difference across the respiratory epithelium. These abnormalities may contribute to the pathogenesis of the disease by reducing the water content of the airway surface liquid, thus impairing mucociliary clearance. Topically applied amiloride blocks entry of sodium into respiratory epithelial cells and reduces the potential difference of the airway epithelium towards normal in patients with cystic fibrosis. This may improve the hydration of the surface liquid. Preliminary evidence from patients with cystic fibrosis suggests that nebulised amiloride reduces sputum viscosity and elasticity and produces transient improvements in the clearance of sputum by mucociliary mechanisms and by coughing, and that regular inhalation reduces the rate of deterioration in forced vital capacity.

The efficacy of nebulised amiloride will depend on the delivery of sufficient quantities of the drug to the airway surface. In sheep the effects of amiloride on the potential difference of the airway epithelium are dose related, maximal effects occurring at high airway surface liquid concentrations; the drug is then cleared rapidly from this site, resulting in a short duration of action. A high initial airway surface concentration of amiloride is therefore likely to be needed to maintain a therapeutic effect between inhalations, and this will require an efficient method of aerosol administration.

In this study we compared the pulmonary deposition of amiloride nebulised from two apparently suitable nebuliser systems. The aim of the study was to determine how much amiloride was delivered to the lungs from each system and which nebuliser would be more suitable for use in clinical trials of amiloride.

Methods

NEBULISERS

The nebulisers selected for the study were System 22 Acorn (Medic-Aid Ltd), a jet nebuliser driven by an air compressor (CR 60, Medic-Aid Ltd) in common use for delivery of nebulised antibiotics, and Fisoneb (Fisons/Medix), a portable hand held ultrasonic nebuliser. Minor modification of the Fisoneb mouthpieces was needed so that a filter could be fitted over the expiratory port to prevent escape of radiolabelled aerosol (additional deadspace 15 ml). The Fisoneb was run at its midpoint setting.

VALIDATION OF THE AMILORIDE MARKER

In the absence of a suitable radiolabelled amiloride analogue, an indirect marker (99mTc colloidal human serum albumin (99mTc HSA, Venticoil)) had to be used to estimate deposition of amiloride in the lung. For this approach to be valid the marker should not affect the mass output of nebulised amiloride or the particle size output of the nebuliser, and it should be distributed in the aerosol cloud like amiloride. This was assessed by
measuring the mass output of the System 22 Acorn nebuliser by nebulising amiloride solution to dryness in the presence and absence of 99mTc HSA and capturing the aerosol cloud by means of a preimpinger and filter. A similar study was not performed for the Fison nebuleiser as the output of ultrasonic nebulisers is underestimated if measured without a subject breathing from the mouthpiece. The amiloride content of washings from the preimpinger and filter (cloud recovery) and nebuliser was measured by spectrophotometry (361 nm). The particle size of the output of amiloride solution from both nebulisers was measured in the presence and absence of 99mTc HSA with a Malvern Master laser particle sizer. An amiloride solution containing 99mTc HSA was nebulised and the cloud sampled with a nine stage cascade impactor. Activities associated with filters from each stage of the cascade impactor (representing particles of different size ranges) were compared with the concentrations of amiloride in washings from these filters. The amiloride content of the filters was determined by gradient high pressure liquid liquid chromatography, 0-1% trifluoroacetic acid in water and 0-1% trifluoroacetic acid in acetonitrile being used. With a flow rate of 2 ml/min amiloride was eluted as a sharp peak at 3-4 minutes, and there was a linear relation between amiloride content and the amiloride peak integral. The mean extraction efficiency of amiloride from the filters was 55% (SD 5%) and was independent of the initial loading concentration.

MEASUREMENT OF PULMONARY AMILORIDE DEPOSITION

Eight adults (six male, two female) with cystic fibrosis volunteered to take part and each gave written informed consent. The study was approved by the ethics committees of the West Lambeth Health District and the Royal Brompton and National Heart Hospital. Each subject was studied on two occasions, with the System 22 on one occasion and Fisoneb on the other. Nebulisers were allocated in random order. Before aerosol inhalation dynamic (five second counting frames) xenon-133 ventilation scanning was performed during breath holding, at equilibrium, and during washout for measurement of total and regional ventilation.

The patients then inhaled aerosol from a nebuliser solution consisting of amiloride 1 mg and 99mTc HSA 50 µg (37 MBq) in a total volume of 3 ml (amiloride concentration 1 mmol/l). During inhalation dynamic scans of the lungs were performed (posterior projection) for measurement of dynamic deposition of aerosol in the lungs. After inhalation static scans were taken of the lungs (anterior and posterior), oropharynx (lateral), and abdomen (anterior and posterior), nebuliser apparatus, and expiratory port filter.

Pulmonary amiloride deposition was calculated from the posterior and anterior lung counts with geometric corrections derived from lung phantom studies.6-11 The fractional exchange of air was calculated on the basis of the Stewart–Hamilton principle,12 by dividing the 133Xe counts at the end of the equilibrium phase by the area under the 133Xe activity-time curve during washout from time zero extrapolated to infinity. The 133Xe counts were corrected for tissue background on the basis of the activity measured over both shoulders. Spirometry was performed before and after aerosol inhalation.

ANALYSIS

All statistical comparisons were made by using a repeated measures analysis of variance. A p value below 0.05 was taken as significant.

Results

The addition of 99mTc HSA to the nebuliser solution did not effect nebuliser mass output or particle size characteristics (table 1). The marker was distributed in particles of differing size ranges in the same way as amiloride (fig 1).

The distribution of 133Xe during breath holding and at equilibrium and the aerosol deposition scans taken from the same patient after each nebuliser had been used are shown in figure 2. Patchy ventilation and aerosol deposition were observed in all patients. The mean (SD) fractional exchange of air during tidal respiration, a measure of regional ventilation, was 1.32 (0.81)%/s in the right lung and 1.36.

Table 1 Mean (SD) particle sizes and mass output of a 3 ml solution of amiloride in water, with and without the addition of 99mTc human serum albumin (HSA), with the two nebulisers

<table>
<thead>
<tr>
<th>System 22</th>
<th>Fisoneb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mass output (cloud recovery (mg); n = 3)</td>
<td>2 mg/ml amiloride</td>
</tr>
<tr>
<td>No HSA</td>
<td>2-62 (0·51)</td>
</tr>
<tr>
<td>With HSA</td>
<td>2-52 (0·45)</td>
</tr>
<tr>
<td>Particle sizes (MMD/span (µm); n = 9)</td>
<td>2 mg/ml amiloride</td>
</tr>
<tr>
<td>No HSA</td>
<td>4·0 (0·2)/2·3 (0·1)</td>
</tr>
<tr>
<td>With HSA</td>
<td>4·2 (0·1)/2·3 (0·1)</td>
</tr>
<tr>
<td>20 mg/ml amiloride (suspension)</td>
<td>5 mg/ml amiloride</td>
</tr>
<tr>
<td>No HSA</td>
<td>3-9 (0·4)/2·3 (0·1)</td>
</tr>
<tr>
<td>With HSA</td>
<td>5·1 (0·1)/1·4 (0·1)</td>
</tr>
</tbody>
</table>

Figure 1 Relation between technetium-99m labelled human serum albumin (99mTc HSA) activity and amiloride content in cascade impactor filters with the Fisoneb (●) and System 22 (○) nebulisers.
(0·92)%/s in the left lung (normal right lung value 3·18 (1·56)%/s$^{12}$); ventilation was greater in the lower than in the upper zones (for example, for the right lung: 1·63 (0·91) v 0·94 (0·61); p < 0·005).

Dynamic lung scans performed during aerosol inhalation (fig 3) showed that deposition of amiloride occurred more rapidly and was completed sooner with the Fisoneb nebuliser (4-5 minutes) than with System 22 nebuliser (6–7 minutes). The total amount of amiloride deposited at the end of the inhalation period was greater with the Fisoneb than with the System 22 nebuliser and this was the case for all lung regions (table 2), especially the central and upper zones. The ratio of central to peripheral deposition (corrected for volume differences on the basis of the $^{133}$Xe counts from each region) did not differ significantly between the two nebulisers (table 2), but deposition of amiloride in the oropharynx and stomach was greater with the Fisoneb nebuliser (table 2).

**Discussion**

In this study we compared the pulmonary deposition of amiloride when given via two apparently suitable nebulisers. These were selected because desirable features of nebul-
users for inhaling amiloride were thought to include a light and portable design with rapid dose delivery, as frequent doses are likely to be required; suitability for administering antibiotics as these will also be used by many patients; a particle size output in the range 3–8 μm, which is small enough to minimise deposition in the upper airways and large enough to minimise deposition in and beyond the terminal bronchi; and the production of adequate pulmonary deposition for a therapeutic effect. Previous studies suggested that the Fisoneb nebuliser met most of these criteria because it is hand held and easily portable and produces a rapid output of appropriately sized particles. The System 22 with a CR60 compressor was also studied because it is issued to many patients with cystic fibrosis for administration of antibiotic prophylaxis and bronchodilators, though it is less portable and thus less attractive for frequent treatments. Only one nebuliser, the System 22 Mixer, is substantially more efficient than those tested here, but it is bulky and thus probably impractical for amiloride treatment.

We assessed the pulmonary deposition of nebulised amiloride with 99mTc HSA as an indirect marker as this did not affect the output of the nebuliser and was distributed in the aerosol cloud in the same way as amiloride. Similar methods have been used to measure the deposition of other agents. Our patients had severe airways disease as indicated by abnormal spirometric values, greatly reduced fractional exchange of air, and uneven regional ventilation. Deposition of aerosol in the lungs was patchy and, as expected, was less in poorly ventilated regions. This confirmed previous reports in children and adults with cystic fibrosis.

With both nebulisers the total amount of amiloride deposited was similar to that seen in association with a short lived effect in dogs and humans, though a lower nebuliser dose was used. The Fisoneb delivered more drug within a shorter time (five minutes) than the System 22 Acorn. It was preferred by the patients because it is quiet and compact. The increased aerosol deposition in the oropharynx, stomach, and central lung region associated with the Fisoneb probably occurs as a consequence of the larger particle sizes produced by this nebuliser. Although more aerosol was swallowed the estimated gastrointestinal dose is unlikely to have a measurable diuretic effect even if completely absorbed. In this study the Fisoneb nebuliser was used at a midpoint setting; use at its maximum setting might reduce nebulisation time but the effects of this on pulmonary aerosol deposition have not been studied.

We cannot say whether therapeutic concentrations of amiloride were achieved in the airways in this study as no pharmacodynamic measurements were made. Experiments in animals and humans suggest that amiloride affects epithelial potential difference and mucociliary clearance over a concentration range of 0.1 μmol/l to 1 mmol/l. It has been estimated that, because of rapid drug clearance, a concentration of at least 5 mmol/l would be required to produce detectable effects lasting five hours. In the clinical study that showed that the deterioration in forced vital capacity of patients with cystic fibrosis could be slowed by the regular administration of inhaled amiloride, however, the dose and nebuliser system used produced an airways surface concentration of only 0.08 mmol/l. Relating these concentrations to a figure for total amiloride deposition is difficult, but in dogs a total deposition of 31 μg was associated with an airways surface concentration of amiloride of 0.03–0.12 mmol/l, and in humans a total deposition of 70 μg produced significant but short lived effects on mucociliary clearance. It seems likely, therefore, that a total deposition substantially greater than 70 μg should be aimed for. The mean amiloride deposition of 102 μg achieved by the Fisoneb under the conditions used in this study probably does not represent a large enough improvement to be associated with a more prolonged effect.

A higher nebuliser dose of amiloride would give greater deposition and probably a larger and more prolonged therapeutic effect. The maximum concentration of amiloride that can be used in nebuliser solutions is limited by its solubility to about 5 mmol/l in saline and, although concentrations of 20 mmol/l can be achieved in water, this has been avoided as hypotonic solutions may provoke bronchoconstriction. The amiloride dose could also be increased by giving a larger volume, but this would take longer to nebulise. A 6.8 mg dose could be given as 4.5 ml of 5 mmol/l solution. This might produce up to 10 times the deposition found in this study because of the higher

---

**Table 3 Effects of inhaled amiloride on lung function: mean values (SD) before and after amiloride with the two nebulisers**

<table>
<thead>
<tr>
<th></th>
<th>System 22</th>
<th>Fisoneb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
</tr>
<tr>
<td>FVC (l)</td>
<td>2.02 (0.85)</td>
<td>1.95 (0.68)</td>
</tr>
<tr>
<td>(Predicted 3-20 (0-24) l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>1.47 (0.82)</td>
<td>1.39 (0.73)</td>
</tr>
<tr>
<td>(Predicted 2-78 (0-24) l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEF (l min⁻¹)</td>
<td>281 (87)</td>
<td>277 (77)</td>
</tr>
<tr>
<td>(Predicted 418 (61) 1 min⁻¹)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For all before versus after amiloride and System 22 versus Fisoneb comparisons p > 0.05 (NS) by analysis of variance.
Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers

Amiloride dose and because of the increased efficiency of nebulising larger volumes, but each treatment would take longer.

Airway abnormalities associated with cystic fibrosis, including gland hypertrophy, duct obstruction and bronchiectasis, have been reported in early infancy. If amiloride has a beneficial preventive effect treatment should logically begin during infancy. Aerosol deposition in infants and children may be affected by different respiration characteristics and the need to use a face mask, so further studies are needed in this age group.

If the clinical benefit suggested by the pilot study is confirmed by larger scale clinical trials, nebulised amiloride may become an important treatment for patients with cystic fibrosis. It would be unfortunate if spuriously negative results were obtained because of inadequate amiloride deposition in the lungs resulting from inefficient nebuliser apparatus or poor compliance by patients. It is important to perform studies such as the one described here before we embark on costly and time consuming clinical trials. The deposition efficiency of other potential methods of administration, such as dry powder inhalation or use of metered dose inhalers, should also be assessed.

Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.

doi: 10.1136/thx.46.10.717

Updated information and services can be found at:
http://thorax.bmj.com/content/46/10/717

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/